This Article Full Text Full Text (PDF) Supplementary Data Correction (v69,p6758) All Versions of this Article: 0008-5472.CAN-09-0236v1 69/14/5970    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Hoffman, A. E. Articles by Zhu, Y. PubMed PubMed Citation Articles by Hoffman, A. E. Articles by Zhu, Y.

microRNA miR-196a-2 and Breast Cancer: A Genetic and Epigenetic Association Study and Functional Analysis

Departments of ¹ Epidemiology and Public Health and ² Therapeutic Radiology, Yale University School of Medicine; ³ Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut

Requests for reprints: Yong Zhu, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520. Phone: 203-785-4844; Fax: 203-737-6023; E-mail: yong.zhu{at}yale.edu.

Key Words: miR-196a-2 • methylation • network analysis • breast cancer

Increasing evidence has suggested that microRNAs (miRNA) play an important role in tumorigenesis. As transcriptional regulators, altered miRNA expression may affect many cancer-related biological pathways, indicating that miRNAs can function as tumor suppressors and/or oncogenes. We first performed a genetic association analysis by screening genetic variants in 15 miRNA genes and detected that a common sequence variant in hsa-miR-196a-2 (rs11614913, CT) was significantly associated with decreased breast cancer risk (for homozygous variant: odds ratio, 0.44; 95% confidence interval, 0.28-0.70). Hypermethylation of a CpG island upstream (-700 bp) of the miR-196a-2 precursor was also associated with reduced breast cancer risk (odds ratio, 0.35; 95% confidence interval, 0.15-0.81). By delivering expression vectors containing either wild-type or mutant precursors of miR-196a-2 into breast cancer cells, we showed that this variant led to less efficient processing of the miRNA precursor to its mature form as well as diminished capacity to regulate target genes. A whole-genome expression microarray was done and a pathway-based analysis identified a cancer-relevant network formed by genes significantly altered following enforced expression of miR-196a-2. Mutagenesis analysis further showed that cell cycle response to mutagen challenge was significantly enhanced in cells treated with variant miR-196a-2 compared with cells treated with the wild-type. Taken together, our findings suggest that miR-196a-2 might have a potentially oncogenic role in breast tumorigenesis, and the functional genetic variant in its mature region could serve as a novel biomarker for breast cancer susceptibility. [Cancer Res 2009;69(14):5970–7]

This article has been cited by other articles:

				Correction: Article on miR-196a-2 in Breast Tumorigenesis Cancer Res., August 15, 2009; 69(16): 6758 - 6758. [Full Text] [PDF]